WorksheetsTRESIBA October 2018
Total questions: 12
Worksheet time: 6mins
The duration of action of Tresiba is .................. with a half life of ...................
beyond 42 hours - 25 hours
beyond 36 hours - 13 hours
beyond 32 hours - 25 hours
beyond 42 hours - 13 hours
The Within day and day to day variability with Tresiba was lower by ................ & ................... vs IGlar U100
20% - 4 times lower.
37% - 70% lower.
40% - 4 times lower.
20% - 50% lower.
The Within day and day to day variability with Tresiba was lower by ................ & ................... vs IGlar U300
37% - 50%
40% - 4 times lower
37% - Aprox. 4 times lower
20% - 4 times lower
Tresiba is an insulin degludec with a structure modification of .....................................................
remove B29 and attach hexadecandiol fatty acid through spacer.
remove A30 and attach hexadecandiol fatty acid through spacer.
remove B30 and attach decandiol fatty acid through spacer.
remove B30 and attach hexadecandiol fatty acid through spacer.
According to BEGIN ONCE LONG trial, Tresiba was compared vs IGlar U100 over .............. for overall .................... , in which A1c at the end was ....................
771 pts. - 2 years - non inferior
1030 type 1 pts. - 2 years - superior
1006 type 2 pts. - 1 year - inferior
1030 type 2 pts. - 2 years - non inferior
BEGIN programme is a phase .............. trials over about ........... aiming to test the ........................... of Tresiba Vs IGlarU100
3b - 11000 pts. - non-inferiority
3a - 9000 pts. - Efficacy
3a - 9000 pts. - non-inferiority
3b - 9000 pts. - non-inferioirty
According to BEGIN Once Long, over 2 years Tresiba has shown a sig. red. in Overall Hypoglycemia 17% & Nocturnal Hypoglycemia by 43% vs IGlar U100
True
False
According to BEGIN BB T2 Trial, 1006 pts. were randomized either onto Tresiba OD vs IGlar U100 OD for 52 weeks followed by 26 weeks , at the end of the trial over all Hypoglycemia and Nocturnal Hypoglycemia were reduced by ............. & ....................... with Tresiba vs IGlar U100
21% - 29%
24% - 36%
24% - 31%
36% - 41%
According to BEGIN BB T1 Trial ........... pts were assigned into Tresiba Vs IGlar U100 + Aspart , at the first year of the trial nocturnal hypoglycemia was reduced by .......... with Tresiba vs IGlar U100 , while after the extension for extra year nocturnal hypoglycemia was reduced by ............. with Tresiba vs IGlar U100
771 - 25% - 36%
501 - 21% - 31%
629 - 25% - 25%
846 - 16% - 24%
According to Ratner et al meta-analysis of the BEGIN programme, the pooled analysis of insulin naive T2DM for over all hypoglycemia was reduced by .............. , Nocturnal Hypoglycemia was reduced by ........... while Severe Hypoglycemia was reduced by .............. with Tresiba vs IGlar U100 Significantly
36 % - 51% - 84%
28% - 49% - 86%
36% - 43% - 82%
18% - 25% - 43%
According to the UKPDS trial 20 years data , 1% reduction in A1c% will help to reduce Myocardial infarctions by ............. Strokes by .................. and Microvascular disease by ..............
10% - 12% - 16%
16% - 12% - 25
12% - 14% - 19%
19% - 21% - 37%
Acute complications of diabetes are ................... , ..................... & ......................
DKA - HONK - Hypoglycemia
Myocardial infractions - Stroke - Cv Death
Nephropathy - Retinopathy- Neuropathy
